201 related articles for article (PubMed ID: 16051735)
41. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
Ravi R; Bedi GC; Engstrom LW; Zeng Q; Mookerjee B; Gélinas C; Fuchs EJ; Bedi A
Nat Cell Biol; 2001 Apr; 3(4):409-16. PubMed ID: 11283615
[TBL] [Abstract][Full Text] [Related]
42. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.
Degli-Esposti MA; Dougall WC; Smolak PJ; Waugh JY; Smith CA; Goodwin RG
Immunity; 1997 Dec; 7(6):813-20. PubMed ID: 9430226
[TBL] [Abstract][Full Text] [Related]
43. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
[TBL] [Abstract][Full Text] [Related]
44. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells.
Hasegawa H; Yamada Y; Komiyama K; Hayashi M; Ishibashi M; Yoshida T; Sakai T; Koyano T; Kam TS; Murata K; Sugahara K; Tsuruda K; Akamatsu N; Tsukasaki K; Masuda M; Takasu N; Kamihira S
Blood; 2006 Jan; 107(2):679-88. PubMed ID: 16195335
[TBL] [Abstract][Full Text] [Related]
45. A study of TRAIL receptors in squamous cell carcinoma of the head and neck.
Teng MS; Brandwein-Gensler MS; Teixeira MS; Martignetti JA; Duffey DC
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):407-12. PubMed ID: 15897419
[TBL] [Abstract][Full Text] [Related]
46. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
47. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
48. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma.
Jeng YM; Hsu HC
Cancer Lett; 2002 Jul; 181(2):205-8. PubMed ID: 12175536
[TBL] [Abstract][Full Text] [Related]
49. On the TRAIL to apoptosis.
Baetu TM; Hiscott J
Cytokine Growth Factor Rev; 2002 Jun; 13(3):199-207. PubMed ID: 12486874
[TBL] [Abstract][Full Text] [Related]
50. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
51. Functional analysis of TRAIL receptors using monoclonal antibodies.
Griffith TS; Rauch CT; Smolak PJ; Waugh JY; Boiani N; Lynch DH; Smith CA; Goodwin RG; Kubin MZ
J Immunol; 1999 Mar; 162(5):2597-605. PubMed ID: 10072501
[TBL] [Abstract][Full Text] [Related]
52. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
53. Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.
Narayan G; Xie D; Ishdorj G; Scotto L; Mansukhani M; Pothuri B; Wright JD; Kaufmann AM; Schneider A; Arias-Pulido H; Murty VV
Genes Chromosomes Cancer; 2016 Feb; 55(2):177-89. PubMed ID: 26542757
[TBL] [Abstract][Full Text] [Related]
54. Different apoptotic regulation of TRAIL-caspase pathway in HBV- and HCV-related hepatocellular carcinoma.
Yano Y; Hayashi Y; Nakaji M; Nagano H; Seo Y; Ninomiya T; Yoon S; Wada A; Hirai M; Kim SR; Yokozaki H; Kasuga M
Int J Mol Med; 2003 Apr; 11(4):499-504. PubMed ID: 12632104
[TBL] [Abstract][Full Text] [Related]
55. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
56. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.
Rokhlin OW; Taghiyev AF; Guseva NV; Glover RA; Syrbu SI; Cohen MB
Cancer Biol Ther; 2002; 1(6):631-7. PubMed ID: 12642685
[TBL] [Abstract][Full Text] [Related]
57. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.
Wu GS; Burns TF; Zhan Y; Alnemri ES; El-Deiry WS
Cancer Res; 1999 Jun; 59(12):2770-5. PubMed ID: 10383128
[TBL] [Abstract][Full Text] [Related]
58. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
[TBL] [Abstract][Full Text] [Related]
59. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin.
Shin EC; Seong YR; Kim CH; Kim H; Ahn YS; Kim K; Kim SJ; Hong SS; Park JH
Exp Mol Med; 2002 May; 34(2):114-22. PubMed ID: 12085986
[TBL] [Abstract][Full Text] [Related]
60. Identification of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) and its receptors in adult rat ventral prostate.
Vindrieux D; Devonec M; Benahmed M; Grataroli R
Mol Cell Endocrinol; 2002 Dec; 198(1-2):115-21. PubMed ID: 12573821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
